MDXG

On the trailing numbers MDXG looks like a bargain: FY2025 revenue grew 20.0% to $419M with GAAP net income of $48.6M, and the growth was broad-based across Wound and Surgical, led by newer products (CELERA, EMERGE, EPIXPRESS). Quality is high — 82.6% gross margin, 15.3% operating margin, 18.9% ROE — and the balance sheet is a fortress: $166M cash (+59%), only $18M total debt, and liabilities/equity of 0.34x. At $3.95 that's 12.3x earnings and 1.4x sales, an undemanding multiple for a profitable double-digit grower with $74M of operating cash flow. Taken alone, those figures argue for a buy.

But the filing itself flags a specific, near-term overhang that the trailing numbers do not yet reflect. Effective January 1, 2026, CMS replaced the ASP+6% skin-substitute reimbursement model with a flat $127.14 per square centimeter rate — described in the MD&A as 'cutting costs by nearly 90%.' Management states plainly it 'anticipate[s] that the 2026 Rules will be a headwind to both Advanced Wound Management sales and profitability in 2026, before any mitigating actions,' and that it may need to tighten inventory and revisit pricing. Since the 2025 acceleration was driven substantially by advanced wound-care products now exposed to this cap, the ~12x P/E is arguably discounting a real forward earnings hit, not a mispricing.